Top Markets
Coin of the day
Aprogen Medicines Inc. Aprogen Medicines Inc.

Aprogen Medicines Inc.

007460
Kedudukan dalam Saham #36621
Founded in 1971 and headquartered in Seongnam-si, South Korea, Aprogen... Founded in 1971 and headquartered in Seongnam-si, South Korea, Aprogen Medicines Inc. (formerly Aprogen KIC Inc. until its name change in April 2021) specializes in the design, manufacture, and maintenance of plant facilities. Their services cater to crucial sectors including steelwork, petrochemistry, shipbuilding, power generation, and liquefied natural gas (LNG) base industries. The company also provides thermal and cold spray services, a diverse range of clad products such as rolls, plates, wear plates, pipes, and fittings, along with plasma transferred arcs. Furthermore, Aprogen Medicines Inc. offers the Nukon system, a specialized heat-preservation solution vital for ensuring the safe operation of internal piping within pressurized water reactor power plant containment buildings. They are also a supplier of Foamglas, a cellular glass insulation product, and undertake fireproof insulation works for furnaces and boilers, notably at POSCO.
Harga Saham
$1.78
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$2.49M
Perubahan (1 hari)
-1.15%
Perubahan (1 tahun)
-98.32%
Negara
KR
Perdagangan Aprogen Medicines Inc. (007460)

Kategori

Hasil untuk Aprogen Medicines Inc. (007460)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Aprogen Medicines Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Aprogen Medicines Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
- -
US
$96.21B -
DE
- -
FR
- -
DE
$21.50B -
US